UY25888A1 - Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias - Google Patents

Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias

Info

Publication number
UY25888A1
UY25888A1 UY25888A UY25888A UY25888A1 UY 25888 A1 UY25888 A1 UY 25888A1 UY 25888 A UY25888 A UY 25888A UY 25888 A UY25888 A UY 25888A UY 25888 A1 UY25888 A1 UY 25888A1
Authority
UY
Uruguay
Prior art keywords
derivatives
mmp
treatment
inhibitors
matrix
Prior art date
Application number
UY25888A
Other languages
English (en)
Inventor
Dr Lorenz Mayr
Dr Bernd Riedl
Dr Rolf Henning
Prof Dr Gunter Benz
Dr Graham Sturton
Dr Kevin Nash
Dr Philip J Gardiner
Dr Mary F Fitzgerald
Dr Helmut Haning
Dr Karl-Heinz Schlemmer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828845.9A external-priority patent/GB9828845D0/en
Priority claimed from GBGB9922709.2A external-priority patent/GB9922709D0/en
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY25888A1 publication Critical patent/UY25888A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Derivados de los ácidos 4-biarilbutírico y 5-biarilpentanoico con actividad inhibitoria de la metalproterasa de la matriz de fórmula general: (T)x-A-B-D-E-CO2H-, donde: (T)x-A representa un resto aromático o heteroaromático sustituido o no sustituido seleccionado de un grupo de los representados en la figura 1, donde R1 es H o alquilo C1-C3 y cada T representa un grupo sustituyente y x es 0, 1 o 2; B representa un enlace o un anillo aromático o heteroaromático opcionalmente sustituido seleccionado de uno de los grupos representados en la figura 2 D es uno de los grupos representados en la figura 3; E es una cadena de 2 o 3 átomos de carbono que lleva de 1 a 3 sustituyentes R6. Ejemplos de derivados seleccionados: Ácido (+)-2-[2-(1,3-dioxo-1,3-dihidro-2H-isoindol-2-il)etil]-4-(4'etoxi-[1,1'-bifenil]-4-il)-4-oxobutanoico; Ácido (+)-4-(4'-cloro[1,1'-bifenil]-4-il)-2-[2-(1,3-dioxo-1,3-dihidro-2H-isoindol-2-il)etil]-4-oxobutanoico; entre otros. Se incluye el uso de los derivados de los ácidos 4-biarilbutírico y 5-biarilpentanoico sustituidos, donde al menos una de lasunidades A, B, T y R6 comprende un anillo heteroaromático como inhibidores de la metaloproteasa de la matriz para la prevención y tratamiento de enfermedades respiratorias, y a composiciones farmacéuticas que los contienen y así como un procedimiento para su uso. En especial estos compuestos pueden ser utilizados para tratar o prevenir trastornos mediados por la MMP-2, MMP-3, MMP9, MMP-12 y/o MMP-1, como entre otras posibilidades para el tratamiento del asma, neuropatía obstructiva crónica, fibrosis quística.
UY25888A 1998-12-30 1999-12-30 Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias UY25888A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828845.9A GB9828845D0 (en) 1998-12-30 1998-12-30 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
GBGB9922709.2A GB9922709D0 (en) 1999-09-24 1999-09-24 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
UY25888A1 true UY25888A1 (es) 2001-08-27

Family

ID=26314942

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25888A UY25888A1 (es) 1998-12-30 1999-12-30 Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias

Country Status (16)

Country Link
US (1) US6900194B1 (es)
EP (1) EP1140768A1 (es)
JP (1) JP2002534404A (es)
KR (1) KR20010101325A (es)
CN (1) CN1337932A (es)
AR (1) AR035472A1 (es)
AU (1) AU1982500A (es)
BR (1) BR9916669A (es)
CA (1) CA2356053A1 (es)
CO (1) CO5261506A1 (es)
HK (1) HK1043981A1 (es)
IL (1) IL143594A0 (es)
PE (1) PE20001339A1 (es)
TR (1) TR200101970T2 (es)
UY (1) UY25888A1 (es)
WO (1) WO2000040539A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
ES2386263T3 (es) 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EA013539B1 (ru) * 2005-02-22 2010-06-30 Рэнбакси Лабораториз Лимитед Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний
US20090118519A1 (en) * 2006-04-17 2009-05-07 Sumitomo Chemical Company, Limited Production Method of Polycyclic Lactams
JP5338035B2 (ja) * 2006-04-17 2013-11-13 住友化学株式会社 多環式ラクタム類の製造方法
AU2011306396A1 (en) * 2010-09-24 2013-05-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN103086947A (zh) * 2011-11-04 2013-05-08 赵庆春 具有抗血管生成活性的邻苯二甲酰亚胺类化合物及其用途
JP5861884B2 (ja) * 2012-03-29 2016-02-16 荒川化学工業株式会社 エキソ型ノルボルネン化合物の製造方法
WO2015150366A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Cyclisch substituierte phenolether-derivate und ihre verwendung
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
CN106661008A (zh) 2014-04-03 2017-05-10 拜耳制药股份公司 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
US20170121315A1 (en) * 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1106195A (en) * 1994-11-09 1996-06-06 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
HRP950558A2 (en) 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
ZA974029B (en) * 1996-05-15 1998-02-19 Bayer Ag Inhibition of matrix metalloproteinases by substituted phenethyl compounds.
JP2002514179A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼの阻害剤としてのビフェニル酪酸およびその誘導体
MY117687A (en) * 1996-10-31 2004-07-31 Bayer Corp Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors
US6399612B1 (en) 1997-10-06 2002-06-04 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases

Also Published As

Publication number Publication date
AU1982500A (en) 2000-07-24
CO5261506A1 (es) 2003-03-31
HK1043981A1 (zh) 2002-10-04
KR20010101325A (ko) 2001-11-14
US6900194B1 (en) 2005-05-31
BR9916669A (pt) 2001-10-16
IL143594A0 (en) 2002-04-21
PE20001339A1 (es) 2001-01-11
CN1337932A (zh) 2002-02-27
AR035472A1 (es) 2004-06-02
EP1140768A1 (en) 2001-10-10
TR200101970T2 (tr) 2002-03-21
CA2356053A1 (en) 2000-07-13
WO2000040539A1 (en) 2000-07-13
JP2002534404A (ja) 2002-10-15

Similar Documents

Publication Publication Date Title
UY25888A1 (es) Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
ECSP055847A (es) Derivados de dihidropiranoindol-3,4-diona sustituidos y derivados de 2-hidroximetilindol del ácido 3-oxoacético sustituidos como inhibidores del inhibidor del activador de plasminógeno 1 (pai-1)
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
BR0109353A (pt) Cadeia lateral heterocìclica contendo inibidores de metaloprotease
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
PE20011314A1 (es) DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
UY27357A1 (es) Nuevos agentes antidiabéticos .
BR0009167A (pt) Inibidores de enzima impdh
BR0011130A (pt) Inibidores de metaloproteases
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
BG106013A (en) New compounds and compositions as protease inhibitors
FI962749A0 (fi) Uusia heterosyklisiä yhdisteitä
ATE284860T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
MA27716A1 (fr) 4-aminopyrimidine-5-one
PE20040698A1 (es) Derivados de isoindolina
CO4820432A1 (es) Composiciones farmaceuticas para el tratamiento de rinitis que comprenden acido 2-(4-(difenilmetil)-1-piperacinil)-ace- tico o amida derivada y un compuesto seleccionado de pseudoe fedrina,fenilpropanolamina y fenilefrina
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
ATE253359T1 (de) Antithrombotische mittel
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
AR044014A1 (es) Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090416